Effects of chronic cannabidiol in a mouse model of naturally occurring neuroinflammation, neurodegeneration, and spontaneous seizures

Cannabidiol (CBD) has gained attention as a therapeutic agent and is purported to have immunomodulatory, neuroprotective, and anti-seizure effects. Here, we determined the effects of chronic CBD administration in a mouse model of CLN1 disease ( Cln1 −/− ) that simultaneously exhibits neuroinflammati...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2022-07, Vol.12 (1), p.11286-11286, Article 11286
Main Authors: Dearborn, Joshua T., Nelvagal, Hemanth R., Rensing, Nicholas R., Takahashi, Keigo, Hughes, Stephanie M., Wishart, Thomas M., Cooper, Jonathan D., Wong, Michael, Sands, Mark S.
Format: Article
Language:English
Subjects:
631/154/152
631/1647/1453/1450
631/1647/664/1257
631/378/371
631/443/319/1642
Adenosine
Animals
Brain research
Cannabidiol
Cannabidiol - pharmacology
Cannabidiol - therapeutic use
Cannabinoids
Chemokines
Convulsions & seizures
Cytokines
Disease Models, Animal
Drug dosages
Gliosis
Graft vs Host Disease - drug therapy
Humanities and Social Sciences
Immunomodulation
Inflammation
Medicine
Mice
multidisciplinary
Narcotics
Neurodegeneration
Neuroinflammatory Diseases
Neuronal Ceroid-Lipofuscinoses
Neuroprotection
Oral administration
Pathology
Proteins
Proteomics
Science
Science (multidisciplinary)
Seizures
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cannabidiol (CBD) has gained attention as a therapeutic agent and is purported to have immunomodulatory, neuroprotective, and anti-seizure effects. Here, we determined the effects of chronic CBD administration in a mouse model of CLN1 disease ( Cln1 −/− ) that simultaneously exhibits neuroinflammation, neurodegeneration, and spontaneous seizures. Proteomic analysis showed that putative CBD receptors are expressed at similar levels in the brains of Cln1 −/− mice compared to normal animals. Cln1 −/− mice received an oral dose (100 mg/kg/day) of CBD for six months and were evaluated for changes in pathological markers of disease and seizures. Chronic cannabidiol administration was well-tolerated, high levels of CBD were detected in the brain, and markers of astrocytosis and microgliosis were reduced. However, CBD had no apparent effect on seizure frequency or neuron survival. These data are consistent with CBD having immunomodulatory effects. It is possible that a higher dose of CBD could also reduce neurodegeneration and seizure frequency.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-022-15134-5